KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cash from Operations: 2009-2024

Historic Cash from Operations for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $572.8 million.

  • Biomarin Pharmaceutical's Cash from Operations rose 66.46% to $368.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $914.0 million, marking a year-over-year increase of 120.40%. This contributed to the annual value of $572.8 million for FY2024, which is 259.69% up from last year.
  • Biomarin Pharmaceutical's Cash from Operations amounted to $572.8 million in FY2024, which was up 259.69% from $159.3 million recorded in FY2023.
  • Over the past 5 years, Biomarin Pharmaceutical's Cash from Operations peaked at $572.8 million during FY2024, and registered a low of $85.4 million during FY2020.
  • Moreover, its 3-year median value for Cash from Operations was $175.9 million (2022), whereas its average is $302.7 million.
  • In the last 5 years, Biomarin Pharmaceutical's Cash from Operations crashed by 42.24% in 2022 and then skyrocketed by 259.69% in 2024.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Cash from Operations stood at $85.4 million in 2020, then skyrocketed by 256.75% to $304.5 million in 2021, then crashed by 42.24% to $175.9 million in 2022, then decreased by 9.46% to $159.3 million in 2023, then surged by 259.69% to $572.8 million in 2024.